New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were

Read the full 326 word article

User Sign In